United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 226.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,933 shares of the biotechnology company's stock after buying an additional 1,341 shares during the period. Avantax Advisory Services Inc.'s holdings in United Therapeutics were worth $596,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of UTHR. AE Wealth Management LLC acquired a new stake in United Therapeutics during the first quarter worth about $248,000. Legato Capital Management LLC purchased a new position in United Therapeutics during the first quarter worth about $1,512,000. KLP Kapitalforvaltning AS boosted its stake in United Therapeutics by 37.6% during the first quarter. KLP Kapitalforvaltning AS now owns 59,600 shares of the biotechnology company's stock worth $18,373,000 after buying an additional 16,300 shares during the period. Allianz Asset Management GmbH boosted its stake in United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after buying an additional 33,254 shares during the period. Finally, IFP Advisors Inc boosted its stake in United Therapeutics by 103.4% during the first quarter. IFP Advisors Inc now owns 1,739 shares of the biotechnology company's stock worth $536,000 after buying an additional 884 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. UBS Group lowered their target price on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday, June 30th. Morgan Stanley lowered their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Bank of America lowered their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald began coverage on shares of United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price on the stock. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $379.69.

United Therapeutics Stock Up 4.2%

United Therapeutics stock traded up $12.16 during trading on Tuesday, reaching $304.81. The stock had a trading volume of 1,142,273 shares, compared to its average volume of 560,610. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The business has a 50 day moving average price of $297.62 and a 200 day moving average price of $312.36. The stock has a market cap of $13.75 billion, a PE ratio of 11.90, a P/E/G ratio of 4.43 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the firm earned $5.85 EPS. The firm's revenue was up 11.7% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity

In other news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the sale, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 70,681 shares of company stock worth $21,318,359 over the last three months. Insiders own 10.30% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.